On the other hand, Snoek et al. described that treatment with specific α7nAChR agonists (AR-R17779 and GSK1345038A) reduced inflammation, such as NF-κB activity and cytokines, but these treatments did not improve the clinical signs of colitis (39), indicating that during colitis the receptor involved in vagal anti-inflammatory effect is still uncertain. The gene discussed is CHRNA7; the disease is colitis.